ither cadaveric or living-donor lobar lung transplantation (LDLTT) is a treatment option for patients with pulmonary hypertension (PH). [1] [2] [3] [4] Right ventricular outflow tract obstruction (RVOTO) is an uncommon complication of lung transplantation, especially for patients with both primary and secondary pulmonary hypertension. [5] [6] [7] [8] An acute decrease in the size of the right ventricular (RV) cavity because of a decrease in pulmonary arterial pressure would contribute to RVOTO and medical management or surgical intervention is required. 5, 7 Disopyramide, an antiarrhythmic drug with a negative inotropic effect, has been reported as effective for alleviation of left ventricular (LV) outflow tract obstruction caused by hypertrophy 9-14 and also for alleviation of RVOTO in a small number of patients with tetralogy of Fallot. 15 However, its efficacy for RVOTO after LDLLT has not been reported. Therefore, we present our experience of a case of RVOTO after LDLLT for which intravenous disopyramide was administered as treatment for the deteriorated hemodynamics.
ither cadaveric or living-donor lobar lung transplantation (LDLTT) is a treatment option for patients with pulmonary hypertension (PH). [1] [2] [3] [4] Right ventricular outflow tract obstruction (RVOTO) is an uncommon complication of lung transplantation, especially for patients with both primary and secondary pulmonary hypertension. [5] [6] [7] [8] An acute decrease in the size of the right ventricular (RV) cavity because of a decrease in pulmonary arterial pressure would contribute to RVOTO and medical management or surgical intervention is required. 5, 7 Disopyramide, an antiarrhythmic drug with a negative inotropic effect, has been reported as effective for alleviation of left ventricular (LV) outflow tract obstruction caused by hypertrophy [9] [10] [11] [12] [13] [14] and also for alleviation of RVOTO in a small number of patients with tetralogy of Fallot. 15 However, its efficacy for RVOTO after LDLLT has not been reported. Therefore, we present our experience of a case of RVOTO after LDLLT for which intravenous disopyramide was administered as treatment for the deteriorated hemodynamics.
Case Report
A 28-year-old female patient with shortness of breath on exercise had been diagnosed with primary pulmonary hypertension (PPH) in 1993, at the age of 18 years. Treatment with beraprost sodium and oxygen treatment was started, but she remained in New York Heart Association functional class III and despite initiation of continuous intravenous prostacyclin therapy in 2001, there was little improvement. Cardiac catheterization revealed that the patient's RV pressure, pulmonary arterial pressure and cardiac index were 114/9 mmHg, 113/36/66 mmHg and 1.7 L·min -1 ·m -2 , respectively. The patient was referred for LDLLT. Preoperative transthoracic echocardiography showed a dilated and hypertrophied right ventricle with hypertrophied septal and parietal bands, but no obstruction of the RVOT.
In December 2002, she underwent LDLLT with a right lower lobe from her father (52 years old) and a left lower lobe from her mother (53 years old). Intraoperative transesophageal echocardiography showed that the RVOT was 1.5 cm in diameter and that there was slight acceleration of its blood flow.
The operation was successful. However, transthoracic echocardiography performed on the fourth postoperative day showed that the velocity of blood flow in the RVOT was 3.1 m/s and it was thought that dehydration and the administration of inotropic agents had augmented the stenosis of the RVOT. Therefore, fluids were administered and the dosages of the inotropic agents were tapered, resulting in slight improvement in peak velocity in the RVOT (2.7 m/s) on the 8th postoperative day.
As her rehabilitation advanced, she developed dyspnea Right ventricular (RV) outflow tract obstruction (RVOTO) is an uncommon complication of lung transplantation in patients with pulmonary hypertension (PH) and both medical management and surgical intervention are required. A 28-year-old female with primary PH was referred and because she did not respond to medical treatment, living-donor lobar lung transplantation was performed. The operation was successful, but dyspnea and exercise intolerance developed during rehabilitation and transthoracic echocardiography revealed RVOTO. Intravenous disopyramide during cardiac catheterization reduced the pressure gradient from 35 mmHg to 16 mmHg without decreasing RV systolic pressure. However, electrical and hemodynamic parameters were adversely affected by disopyramide and thus, after cardiac catheterization, administration of fluid and a low dose of atenolol was started, and her symptoms improved. Transthoracic echocardiography showed improvement in the RVOTO. This case suggests that disopyramide should be avoided for patients with RVOTO following lung transplantation and that other negative inotropic agents, such as -blockers, are more effective for relief of RVOTO. (Fig 1) ; the peak velocity of blood flow in the RVOT was 4.0 m/s. Thus, we considered that her symptoms were caused by the worsening of the RVOTO. Cardiac catheterization confirmed the RVOTO (Fig 2) , and the pressure gradient through the RV outflow tract was 35 mmHg. Dysopyramide (2 mg/kg) was administered intravenously at the rate of 10 mg/min, 10, 13 and the pressure gradient in the RVOT immediately decreased to 16 mmHg. However, the reduction was achieved only by an increase in pulmonary arterial systolic pressure without a decrease in the RV systolic pressure. Moreover, cardiac output decreased and mechanical and electrical alternans appeared (Table 1, Fig 3) . Administration of intravenous disopyramide was not beneficial for this patient. After cardiac catheterization, fluid administration and treatment with a low dosage of atenolol (12.5 mg/day) were started, and her symptoms improved. Repeated transthoracic echocardiography revealed improvement in the RVOTO, with a reduction in the peak flow velocity to 3.2 m/s and no mechanical alternans in the flow profile of the RVOT.
Discussion
This is the first case report of RVOTO after LDLLT. Symptomatic severe RVOTO is an uncommon complication after cadaveric lung transplantation for patients with PH, causing right heart failure. [5] [6] [7] [8] Only 8 cases have been reported. Long-standing PH induces significant structural changes in the heart such as marked RV hypertrophy and enlargement, 16 and in such patients, lung transplantation causes a rapid reduction in the RV afterload, which in turn causes a rapid decrease in the size of the hypertrophied right ventricle, 16 resulting in acquired RVOTO. [5] [6] [7] [8] The usefulness of a preoperative echocardiographic study for predicting postoperative RVOTO has not been clarified. Postoperative administration of inotropic agents may also induce RVOTO and in such cases, dramatic improvement occurs when the administration is discontinued. Once RVOTO occurs, medical treatment, such as ablocker or a calcium channel antagonist, is required until RV remodeling and regression of the hypertrophy have been completed. 5 These agents are thought to be effective because they reduce contractility, improve the intrinsic diastolic function and increase the diastolic filling time. Myectomy and outflow tract patching have been performed in 2 patients with RVOTO after cadaveric lung transplantation. 7 Disopyramide has been reported as effective for reducing the pressure gradient and improving the diastolic properties in patients with hypertrophic cardiomyopathy, [10] [11] [12] [13] [14] consequently, reducing the severity of the clinical symptoms. Its effectiveness not only for LV outflow tract obstruction, but also for treatment of RVOTO in a small number of patients with tetralogy of Fallot, has been reported. 15 In the case of hypertrophic cardiomyopathy, the reduction in the pressure gradient is achieved through a decrease in LV systolic pressure and a rise in aortic systolic pressure, which may reflect an increase in systemic vascular resistance. 10, 12, 13 The mechanism by which the pressure gradient through the LV outflow tract is reduced by disopyramide is thought to be a negative inotropic effect and increased systemic vascular resistance. 10 The decrease in the intracellular Ca 2+ concentration because of inhibition of the Na + influx would contribute to the negative inotropic effect 17 and to the improvement in diastolic properties. 18 It has also been reported that cibenzoline attenuated the biventricular pressure gradients in patient with hypertrophic cardiomyopathy. 19 Therefore, we expected that disopyramide would also improve the RVOTO after LDLLT and indeed, the pressure gradient through the RVOT was reduced immediately after the injection of disopyramide. However, this reduction was achieved only by an increase in pulmonary arterial systolic pressure, and the RV systolic pressure remained high. In other words, disopyramide only increased the pulmonary vascular resistance and had almost no negative inotropic effect on the right ventricle.
We do not know why disopyramide failed to improve RVOTO in the present case. Unlike hypertrophic obstructive cardiomyopathy, the RVOTO after LDLLT develops because of the rapid decrease in the size of the cavity of the hypertrophied right ventricle. Moreover, in this case the RVOT in diastole was very narrow because of the rapid reduction in preload and afterload of the right ventricle. Therefore, it is possible that disopyramide could not induce a sufficient negative inotropic effect to relieve the mechanical obstruction.
The present results suggest that disopyramide should not be given to patients with RVOTO following lung transplantation and that other negative inotropic agents, such as -blockers, and adequate fluid therapy will relieve the obstruction.
